DHEA

See our Evidence Standards for how we grade the research below.

What It Is

Dehydroepiandrosterone (DHEA) is a steroid hormone produced mainly by the adrenal glands, and one of the most abundant circulating steroids in the body. It functions largely as a precursor: peripheral tissues convert DHEA into androgens and estrogens locally, so its downstream effects depend heavily on which conversion pathways are active in a given tissue. DHEA levels decline substantially with age in both sexes, which is part of why it's been studied as a potential intervention for age-related changes in body composition, sexual function, and wellbeing. DHEA and its sulfate form (DHEA-S) are also classified as neurosteroids: they're synthesized directly in the brain, not only peripherally, and act on GABA-A, NMDA, and sigma-1 receptors, a mechanism distinct from the pathway where DHEA is converted into testosterone or estradiol elsewhere in the body. This neurosteroid activity is the proposed mechanism behind DHEA's studied effects on mood, discussed below. DHEA also has documented immunomodulating activity, including effects on cytokine production and T-cell function, which is why it's been studied both in autoimmune disease (below) and as a potential way to counter age-related immune decline, with mixed results discussed below as well.

Route and indication change the evidence picture substantially. The two meta-analyses below cover systemic (oral) DHEA for broad effects like energy, mood, body composition, and overall sexual function. Local, vaginal DHEA and DHEA studied specifically in lupus are different stories, each covered in its own section below, with their own distinct evidence and regulatory history. Treating "DHEA" as one undifferentiated intervention obscures real differences between these uses.
A quick note on "normal." DHEA reference ranges are wide and decline steadily with age for everyone, so a level that clears the standard age-adjusted range does not tell you whether a given patient is functioning at their own personal baseline, only that they resemble their age peers. A result inside that broad range can still leave someone short of where their energy, mood, or body composition would sit at a more youthful level; that is a description of population aging, not proof a specific patient is optimized. More on this idea across every hormone on this site is in the Cellular Medicine framework.

The Evidence — Systemic (Oral) DHEA

Corona G, Rastrelli G, Giagulli VA, Sila A, Sforza A, Forti G, Mannucci E, Maggi M. "Dehydroepiandrosterone Supplementation in Elderly Men: A Meta-Analysis Study of Placebo-Controlled Trials." Journal of Clinical Endocrinology & Metabolism. 2013 Sep;98(9):3615-3626. PMID: 23824417. Meta-analysis of 25 double-blind, placebo-controlled RCTs, 1,353 elderly men, mean follow-up 36 weeks. DHEA supplementation was associated with a small reduction in fat mass, but this effect disappeared in a multivariate model once the authors adjusted for DHEA's conversion into testosterone and estradiol, suggesting the effect, where present, is mediated through those downstream hormones rather than DHEA acting directly. No effect was found on lipid or glycemic metabolism, bone health, sexual function, or quality of life.

Meta-analysis of 25 RCTs (N=1,353) Endpoint: Clinical outcome (body composition, sexual function, QoL)

Villareal DT, Holloszy JO. "Effect of DHEA on Abdominal Fat and Insulin Action in Elderly Women and Men: A Randomized Controlled Trial." JAMA. 2004 Nov 10;292(18):2243-2248. PMID: 15536111. Randomized, double-blind, placebo-controlled trial, 56 elderly adults (28 women, 28 men, mean age 71), given 50 mg/day DHEA or placebo for 6 months. Visceral and subcutaneous abdominal fat were measured directly by MRI, and insulin sensitivity was assessed by oral glucose tolerance test. DHEA produced a significant reduction in visceral fat area compared with placebo (-13 cm² vs. +3 cm², P=.001), a significant reduction in subcutaneous fat (-13 cm² vs. +2 cm², P=.003), and significantly improved insulin sensitivity (P=.007).

This trial almost certainly sits inside the pool of 25 studies in the Corona 2013 meta-analysis above, which found DHEA's effect on fat mass attenuated once hormone conversion was accounted for across the full body of evidence. Both findings are legitimate; they're measuring different things at different levels of precision. This trial used MRI to isolate visceral fat specifically over 6 months in a single well-controlled cohort. The meta-analysis pooled a broader, coarser "fat mass" measure across 25 more heterogeneous trials. A single well-designed trial finding a real effect and a meta-analysis finding the pooled effect wash out are not necessarily in contradiction, that's often exactly what happens when a genuine but modest effect gets diluted by less precise measurement and mixed populations across many smaller studies. We think this is a real, promising result worth another dedicated trial to confirm at scale, not a settled contradiction of the broader meta-analysis.
RCT (N=56) Endpoint: Clinical outcome (MRI-measured visceral fat, insulin sensitivity)

Peixoto C, Grande AJ, Carrilho CG, Nardi AE, Cardoso A, Veras AB. "Dehydroepiandrosterone for Depressive Symptoms: A Systematic Review and Meta-Analysis of Randomized Controlled Trials." Journal of Neuroscience Research. 2020 Dec;98(12):2510-2528. PMID: 32930419. Systematic review of 15 RCTs (853 individuals, both sexes, with depression or depressive symptoms occurring alongside other psychiatric or medical conditions); 12 of those studies (742 individuals) were pooled in meta-analysis. DHEA significantly improved depressive symptoms compared with placebo (standardized mean difference -0.28, 95% CI -0.45 to -0.11, p=.001), a small-to-moderate effect with reasonably consistent direction across studies. The largest effects were seen in people with a formal diagnosis of depression or dysthymia, rather than depressive symptoms occurring as part of another condition. Side effects were uncommon, mild, and mostly androgenic. The review authors rated the overall quality of the underlying evidence as very low, reflecting small individual trial sizes and mixed populations, despite the statistically significant pooled result.

Meta-analysis of 12 RCTs (N=742), authors rate evidence quality very low Endpoint: Clinical outcome (depressive symptom severity)

Danenberg HD, Ben-Yehuda A, Zakay-Rones Z, Gross DJ, Friedman G. "Dehydroepiandrosterone Treatment Is Not Beneficial to the Immune Response to Influenza in Elderly Subjects." Journal of Clinical Endocrinology & Metabolism. 1997 Sep;82(9):2911-2914. PMID: 9284718. DHEA has documented immunomodulating mechanisms, including suppression of IL-6 and effects on T-cell cytokine production, and it was shown to reverse age-related decline in vaccine response in aged rodents, which is why this trial was designed. Randomized, double-blind trial, 71 elderly volunteers (61-89 years old), given DHEA (50 mg/day for four days around the time of vaccination) or placebo, testing antibody response to influenza vaccination. DHEA treatment raised serum DHEA-S as expected but produced no enhancement of vaccine immunity. Among participants with a non-protective baseline antibody titer, those given DHEA were significantly less likely to reach a protective titer than those given placebo (52% vs. 84%, P<0.05), a signal in the wrong direction rather than simply a null result. There was no difference in influenza-like illness between groups over the following winter.

RCT (N=71) Endpoint: Clinical outcome (vaccine antibody response, a real animal-to-human translation test)

Scheffers CS, Armstrong S, Cantineau AEP, Farquhar C, Jordan V. "Dehydroepiandrosterone for Women in the Peri- or Postmenopausal Phase." Cochrane Database of Systematic Reviews. 2015 Jan 8;(1):CD011066. Cochrane systematic review of RCTs of DHEA supplementation in peri- and postmenopausal women. The review found no evidence that DHEA improves quality of life, found uncertain evidence for an effect on menopausal symptoms, and found low-certainty evidence that DHEA may slightly improve sexual function compared with placebo. Androgenic side effects (acne, oily skin, unwanted hair growth) were more common with DHEA than placebo. The review authors noted publication bias as a real possibility, since studies that failed to find a sexual-function benefit may be underrepresented in what's been published.

Cochrane systematic review of RCTs Endpoint: Clinical outcome (QoL, menopausal symptoms, sexual function)

The Evidence — Local (Vaginal) DHEA

Labrie F, Archer DF, Koltun W, et al.; VVA Prasterone Research Group. "Efficacy of Intravaginal Dehydroepiandrosterone (DHEA) on Moderate to Severe Dyspareunia and Vaginal Dryness, Symptoms of Vulvovaginal Atrophy, and of the Genitourinary Syndrome of Menopause." Menopause. 2016 Mar;23(3):243-256. PMID: 26731686. Prospective, randomized, double-blind, placebo-controlled Phase III trial. 482 postmenopausal women in the intent-to-treat population (325 DHEA, 157 placebo) used daily intravaginal DHEA (6.5 mg) or placebo. The trial measured four co-primary endpoints specified by the FDA: percentage of parabasal cells, percentage of superficial cells, vaginal pH, and patient-reported moderate-to-severe dyspareunia. Intravaginal DHEA produced clinically and statistically significant improvement on all four. This trial, and others like it, formed the basis for FDA approval of intravaginal DHEA (prasterone, brand name Intrarosa) in 2016 for moderate-to-severe dyspareunia due to vulvovaginal atrophy. Serum hormone levels stayed within the normal postmenopausal range with this local, low-dose route, distinguishing it from the systemic effects (and systemic evidence gaps) discussed above.

Large Phase III RCT (N=482) Endpoint: Clinical outcome (FDA-specified co-primary endpoints, including patient-reported pain)

The Evidence — DHEA in Lupus (SLE)

Crosbie D, Black C, McIntyre L, Royle PL, Thomas S. "Dehydroepiandrosterone for Systemic Lupus Erythematosus." Cochrane Database of Systematic Reviews. 2007 Oct 17;(4):CD005114. Cochrane systematic review of 7 RCTs, 842 people with SLE (predominantly women), comparing DHEA (mostly as prasterone/GL701, 200 mg/day) to placebo. DHEA showed little clinical effect on disease activity in people with mild-to-moderate disease, though one included trial found more patients stabilized or improved on DHEA than placebo. There was a modest but clinically meaningful improvement in patient-reported quality of life (moderate-quality evidence). DHEA may improve disease activity in people with severe or active disease, but that finding rests on low-quality evidence. Adverse events, especially androgenic ones like acne, were significantly more common with DHEA (roughly double the risk versus placebo). Organ damage from lupus itself wasn't measured in the included trials, so DHEA's effect on that outcome remains unknown.

This has a genuinely interesting regulatory history worth knowing. Based on this and related trial data, the FDA granted prasterone (branded Prestara) "approvable" status for lupus in 2001, specifically for reducing corticosteroid requirements and preserving bone density in women on chronic glucocorticoid therapy, contingent on one additional confirmatory Phase III trial. That trial was never completed; the sponsor could not secure funding for it, and the drug was never actually approved. DHEA remains unapproved for lupus in the US today, not because a trial failed, but because a required trial was never finished.
Cochrane review of 7 RCTs (N=842) Endpoint: Clinical outcome (disease activity, QoL, adverse events)

What's Reported in Practice

Anecdotal / clinical experience, not yet trial-tested

Beyond the confirmed local benefit for vulvovaginal atrophy, patients on systemic DHEA sometimes report improved energy, mood, libido, and body composition, particularly when it's used alongside other hormone optimization. Mood and visceral fat reduction now both have real, positive trial evidence behind them, discussed above, though the strength of that evidence differs (mood: statistically significant meta-analysis rated low-quality by its own authors; visceral fat: one well-designed but small trial that sits in tension with a larger, more mixed meta-analysis). Energy and libido broadly remain the weakest-supported part of the systemic picture: two separate meta-analyses, in men and in women, largely didn't find those broader benefits patients sometimes describe.

What the Research Doesn't Yet Show

This is where we're most eager to see more research investment, not a mark against the compound, and it's genuinely a mixed picture rather than a uniformly weak one. Local, vaginal DHEA has strong, FDA-approved evidence for one specific indication, dyspareunia from vulvovaginal atrophy, and that part of the evidence base is solid. Mood and visceral fat are both real middle-ground findings: statistically significant, biologically plausible, and worth taking seriously, but each with a real caveat attached, very low-quality underlying evidence for mood, and a small single trial in tension with a larger pooled analysis for visceral fat. Neither is settled, and both deserve a larger, dedicated trial to confirm. The broadest systemic claims, general energy, quality of life, and sexual function in men, are where the evidence is weakest: the men's meta-analysis found DHEA's effect on overall fat mass disappeared once downstream hormone conversion was accounted for, meaning DHEA itself may not be doing much systemically beyond what a more targeted intervention could do more predictably. The women's Cochrane review found DHEA's clearest possible systemic benefit, sexual function, rests on low-certainty evidence with a real risk of publication bias. Both systemic reviews are also limited by relatively short follow-up (well under a year in most included trials), so DHEA's long-term systemic effects, positive or negative, remain genuinely unknown. The systemic-use gap looks less like a compound the field hasn't gotten around to studying yet, and more like one where the studies that exist haven't found what practice experience suggests, which is exactly the kind of finding that deserves a larger, longer, well-designed trial to resolve rather than being dismissed in either direction.

Compounded and FDA-approved formulations both exist for DHEA; specific product, route, and dose are individualized based on your history and goals, and discussed at your visit.

Next Step

This page covers mechanism and evidence. Dosing, formulation, and whether this is appropriate for you are individual clinical decisions made with your provider.

Already a patient? Bring this up at your next 4Ever Young visit. Have a question first?

Linktree DM on Instagram Email Dr. Wilcox